MIALA R OLIGER NP
Prescription History 1881978112
Nurse Practitioner - Family in Bloomington, IN

NPI Status: Active since October 05, 2011

Contact Information

2605 E CREEKS EDGE DR
BLOOMINGTON, IN
ZIP 47401
Phone: (812) 355-2300

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MIALA R OLIGER NP, an active Family specialist practicing in Bloomington, IN. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 343 documented patient claims. Among these therapy options, the most frequently utilized medication is Alendronate Sodium, which accounts for 185 claims alone.

Medication Index


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 185
30-Day Fills 468.0
Days Supply 13,947
IN State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills108.5
Peer Average Days Supply3,195
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 285.4% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,683.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.10

State Avg Cost Per Claim

$10.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Amiloride Hcl

Generic Formulation: Amiloride HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 27
30-Day Fills 57.0
Days Supply 1,710
IN State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills35.1
Peer Average Days Supply943
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.6% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,247.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$46.19

State Avg Cost Per Claim

$19.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Amiloride is used with other water pills/diuretics (such as furosemide, thiazide diuretics like hydrochlorothiazide) to treat high blood pressure (hypertension), heart failure, or extra fluid in the body (edema). Amiloride also helps to treat or prevent low blood potassium levels caused by the other diuretics. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Amiloride is called a water pill (diuretic) and causes your body to get rid of extra salt and water while also preventing the kidneys from getting rid of too much potassium.

Chlorthalidone

Generic Formulation: ChlorthalidoneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 24.0
Days Supply 720
IN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills70.8
Peer Average Days Supply2,105
Conservative Utilization

This provider writes prescriptions for this formulation 44.8% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $96.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.00

State Avg Cost Per Claim

$26.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.

Therapeutic Applications

Chlorthalidone is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to reduce extra salt and water in the body caused by conditions such as heart failure, liver disease, and kidney disease. Decreasing extra salt and water in the body helps to decrease swelling (edema) and breathing problems caused by fluid in the lungs. Chlorthalidone is a water pill (diuretic). It increases the amount of urine you make, especially when you first start the medication. It also helps to relax the blood vessels so that blood can flow more easily.

Forteo

Generic Formulation: TeriparatideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 23.6
Days Supply 672
IN State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.4
Peer Average Days Supply664
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $104,595.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,229.79

State Avg Cost Per Claim

$4,426.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Therapeutic Applications

Teriparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication is not recommended for use in children or young adults whose bones are still growing.

Ibandronate Sodium

Generic Formulation: Ibandronate SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 23
30-Day Fills 59.0
Days Supply 1,768
IN State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills52.5
Peer Average Days Supply1,572
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,004.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.66

State Avg Cost Per Claim

$55.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.

Therapeutic Applications

Ibandronate is used to prevent and treat certain types of bone loss (osteoporosis). Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause, as you age, or if you take corticosteroid medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Ibandronate belongs to a class of medications called bisphosphonates.

Raloxifene Hcl

Generic Formulation: Raloxifene HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 27
30-Day Fills 74.1
Days Supply 2,197
IN State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills46.2
Peer Average Days Supply1,354
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 35.0% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,690.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.61

State Avg Cost Per Claim

$98.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Therapeutic Applications

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

Tymlos

Generic Formulation: AbaloparatideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 45
30-Day Fills 45.0
Days Supply 1,350
IN State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.4
Peer Average Days Supply851
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 73.1% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $119,800.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,662.23

State Avg Cost Per Claim

$2,651.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Abaloparatide is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. It is similar to a natural hormone in your body (parathyroid hormone). It works by increasing bone mass and strength. This effect helps to decrease the risk of getting a fracture. This medication should not be used for children or young adults whose bones are still growing.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MIALA R OLIGER NP provides transparency into local medical care patterns within Bloomington, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.